The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy

被引:23
作者
Setordzi, Patience [1 ]
Chang, Xing [1 ]
Liu, Zi [1 ]
Wu, Yingliang [1 ]
Zuo, Daiying [1 ]
机构
[1] Shenyang Pharmaceut Univ, Dept Pharmacol, 103 Wenhua Rd, Shenyang 110016, Peoples R China
基金
中国国家自然科学基金;
关键词
PD-1/PD-L1; Breast cancer; Immunotherapy; Monotherapy; Combination therapies; PROGRAMMED DEATH 1; TUMOR-INFILTRATING LYMPHOCYTES; ANDROGEN RECEPTOR; COMBINATION STRATEGIES; ANTI-PD-L1; ANTIBODY; DOSE-ESCALATION; EXPRESSION; BLOCKADE; PEMBROLIZUMAB; APOPTOSIS;
D O I
10.1016/j.ejphar.2021.173867
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Over the past decade, there has been sustained research activity on programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors for breast cancer (BC) immunotherapy. Several clinical studies have demonstrated the anti-tumor efficacy of monotherapy drugs targeting PD-1 and PD-L1 checkpoint signaling in BC. Besides, the combination of anti-PD-1/PD-L1 agents with other inhibitors, including polyadenosine diphosphate-ribose polymerase (PARP) inhibitors, vaccines, mitogen-activated protein kinase (MEK) inhibitors, and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors are being investigated to improve drug efficacy. These trials have performed well and have shown better and more sustainable therapeutic responses. As follows, the purpose of this review is to discuss the recent advances in BC immunotherapy targeting the inhibition of PD-1/PD-L1 immune checkpoint signaling, when recommended as a monotherapy or in conjunction with other treatments. We look forward to providing new insights into the current state of BC research and the future direction of PD-1/PD-L1 immune checkpoint signaling.
引用
收藏
页数:14
相关论文
共 156 条
  • [21] Immune Checkpoint Blockade in Breast Cancer Therapy
    Bu, Xia
    Yao, Yihui
    Li, Xiaoyu
    [J]. TRANSLATIONAL RESEARCH IN BREAST CANCER: BIOMARKER DIAGNOSIS, TARGETED THERAPIES AND APPROACHES TO PRECISION MEDICINE, 2017, 1026 : 383 - 402
  • [22] Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
    Buchbinder, Elizabeth
    Hodi, F. Stephen
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09) : 3377 - 3383
  • [23] Androgen Receptor (AR) Physiological Roles in Male and Female Reproductive Systems: Lessons Learned from AR-Knockout Mice Lacking AR in Selective Cells
    Chang, Chawnshang
    Lee, Soo Ok
    Wang, Ruey-Sheng
    Yeh, Shuyuan
    Chang, Ta-Min
    [J]. BIOLOGY OF REPRODUCTION, 2013, 89 (01)
  • [24] Regulation of PD-L1: a novel role of pro-survival signalling in cancer
    Chen, J.
    Jiang, C. C.
    Jin, L.
    Zhang, X. D.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (03) : 409 - 416
  • [25] Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
    Chen, Lieping
    Han, Xue
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09) : 3384 - 3391
  • [26] Critical role of CDK11p58 in human breast cancer growth and angiogenesis
    Chi, Yayun
    Huang, Sheng
    Peng, Haojie
    Liu, Mengying
    Zhao, Jun
    Shao, Zhiming
    Wu, Jiong
    [J]. BMC CANCER, 2015, 15
  • [27] New immunotherapies targeting the PD-1 pathway
    Chinai, Jordan M.
    Janakiram, Murali
    Chen, Fuxiang
    Chen, Wantao
    Kaplan, Mark
    Zang, Xingxing
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (09) : 587 - 595
  • [28] Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
    Chretien, Sebastian
    Zerdes, Ioannis
    Bergh, Jonas
    Matikas, Alexios
    Foukakis, Theodoros
    [J]. CANCERS, 2019, 11 (05)
  • [29] Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer
    Cyprian, Farhan S.
    Akhtar, Saghir
    Gatalica, Zoran
    Vranic, Semir
    [J]. BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2019, 19 (03) : 227 - 233
  • [30] Dai XF, 2015, AM J CANCER RES, V5, P2929